普伐他汀对早期中老年急性冠脉综合征的疗效研究

摘要

目的 观察中老年急性冠脉综合征(ACS)患者早期应用中等剂量普伐他汀的临床意义.方法 选择中老年ACS患者107例,随机分为3组.在常规治疗的基础上A组采用普伐他汀40 mg治疗;B组采用阿托伐他汀40 mg治疗;C组采用阿托伐他汀80 mg治疗.3组疗程均为3个月,比较3组患者的外周血脂浓度、凝血功能、肝功能和药物不良反应,随访1年,观察心血管事件发生率.结果 3组患者治疗后血总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、纤溶酶原激活物抑制剂(PAI-1)水平、组织型纤溶酶原激活剂(t-PA)活性比较,差异均有统计学意义(P＜0.05).其中治疗后A组与B组TC、LDL-C、PAI-1、HDL-C、t-PA比较,差异均有统计学意义(P＜0.05);A组与C组t-PA比较,差异有统计学意义(P＜0.05).随访1年3组心血管事件发生率比较,差异有统计学意义(P＜0.05).3组不良反应发生率比较,差异有统计学意义(P＜0.05),其中C组高于A组,差异有统计学意义(P＜0.05).结论 中等剂量普伐他汀应用于中老年早期ACS的疗效优于常规剂量阿托伐他汀,不良反应和1年内心血管事件发生率较低.%Objective To investigate the clinic efficacy of middle - dose pravastatin in acute coronary syndrome ( ACS ) treatment among middle and old aged patients.Methods One hundred and seven senile ACS patients were divided randomly into three groups.In addition to conventional treatment, patients in group A received pravastatin 40 mg qn, pravastatin 40 mg qn for group B, and simvastatin 80 mg qn for group C.Peripheral lipid concentrations, coagulation function, liver function and adverse drug effects were observed after 3 months of treatment.Incidence of cardiovascular events were observed for one year through follow - up.Results After treatment, levels of cholesterol ( TC ), low - density lipoprotein cholesterol ( LDL - C ), high - density lipoprotein cholesterol ( HDL - C ), t - PA and PAI - 1 were statistically different among the 3 groups ( P ＜ 0.05 ).Incidence of adverse events and cardiovascular events within one year were also statistically different among the 3 groups ( P ＜ 0.05 ).Conclusion Middle - dose pravastatin is more effective in lowering lipid levels, maintaining normal coagulation function and liver function, and reducing incidence of cardiovascular events.